Impact of prior ALK-tyrosine kinase inhibitor on pemetrexed-based chemotherapy in patients with advanced ALK positive non-small cell lung cancer.

被引：0
作者：
Yabe, Michitoshi
Kenmotsu, Hirotsugu
Kodama, Hiroaki
Nishioka, Naoya
Miyawaki, Eriko
Miyawaki, Taichi
Mamesaya, Nobuaki
Kobayashi, Haruki
Omori, Shota
Wakuda, Kazushige
Ono, Akira
Naito, Tateaki
Murakami, Haruyasu
Takahashi, Toshiaki
机构：
[1] Shizuoka Canc Ctr, Sunto Gun, Japan
[2] Shizuoka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan
[3] Shizuoka Canc Ctr, Shizuoka, Japan
[4] Shizuoka Canc Ctr, Div Thorac Oncol, Sunto Gun, Shizuoka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e21113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21113
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Efficacy and safety of lorlatinib in patients (pts) with ALK plus non-small cell lung cancer (NSCLC) with one or more prior ALK tyrosine kinase inhibitor (TKI): A phase I/II study
    Shaw, Alice Tsang
    Ou, Sai-Hong Ignatius
    Felip, Enriqueta
    Bauer, Todd Michael
    Besse, Benjamin
    Gadgeel, Shirish M.
    Camidge, D. Ross
    Lin, Chia-Chi
    Seto, Takashi
    Soo, Ross A.
    Chiari, Rita
    James, Leonard P.
    Clancy, Jill S.
    Martini, Jean-Francois
    Abbattista, Antonello
    Pithavala, Yazdi K.
    Solomon, Benjamin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] Efficacy of tyrosine kinase inhibitors (TKIs) based on the ALK resistance mutations on amplicon-based liquid biopsy in ALK positive non-small cell lung cancer (NSCLC) patients (pts).
    Mezquita, Laura
    Swalduz, Aurelie
    Jovelet, Cecile
    Ortiz-Cuaran, Sandra
    Planchard, David
    Recondo, Gonzalo
    Carlos Benitez, Jose
    Howarth, Karen
    Morris, Clive D.
    Green, Emma
    Lacroix, Ludovic
    Odier, Luc
    Rouleau, Etienne
    Fournel, Pierre
    Caramella, Caroline
    Tissot, Claire
    Perol, Maurice
    Friboulet, Luc
    Besse, Benjamin
    Saintigny, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Treatment of ALK-Positive Non-Small Cell Lung Cancer
    Bang, Yung-Jue
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1201 - 1204
  • [34] Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis
    Chiari, Rita
    Metro, Giulio
    Iacono, Daniela
    Bellezza, Guido
    Rebonato, Alberto
    Dubini, Alessandra
    Sperduti, Isabella
    Bennati, Chiara
    Paglialunga, Luca
    Burgio, Marco Angelo
    Baglivo, Sara
    Giusti, Raffaele
    Minotti, Vincenzo
    Delmonte, Angelo
    Crino, Lucio
    LUNG CANCER, 2015, 90 (02) : 255 - 260
  • [35] Predictors of delays in initiation of oral tyrosine kinase inhibitors (TKIs) in EGFR and ALK positive advanced non-small cell lung cancer (NSCLC).
    Goulart, Bernardo H. L.
    Chennupati, Shasank
    Egan, Kathryn
    Fedorenko, Catherine R.
    Ramsey, Scott David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [36] BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA
    Rosado-Buzzo, A.
    Garcia-Mollinedo, L.
    Luna-Casas, G.
    Mould-Quevedo, J. F.
    Gutierrez-Ardila, M., V
    Vargas Zea, N.
    VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
  • [37] Treating ALK-positive non-small cell lung cancer
    Ziogas, Dimitrios C.
    Tsiara, Anna
    Tsironis, Georgios
    Lykka, Maria
    Liontos, Michalis
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [38] Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review
    Lin, Yen-Ting
    Yu, Chong-Jen
    Yang, James Chih-Hsin
    Shih, Jin-Yuan
    CLINICAL LUNG CANCER, 2016, 17 (05) : E77 - E94
  • [39] Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy
    Xin-min Zhao
    Jing Zhao
    Xiang-hua Wu
    Zhi-guo Luo
    Hui-jie Wang
    Hui Yu
    Jian-hua Chang
    Jia-lei Wang
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 851 - 860
  • [40] Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy
    Zhao, Xin-min
    Zhao, Jing
    Wu, Xiang-hua
    Luo, Zhi-guo
    Wang, Hui-jie
    Yu, Hui
    Chang, Jian-hua
    Wang, Jia-lei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (04) : 851 - 860
12345